Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith S Currier

Showing results (211-220 of 298) with videos related to

Pageof 30
Sort By:
Pathogens & Immunity|May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 TrialKatya C Corado, Kara W Chew, Mark J Giganti, et al.
AIDS (London, England)|June 26, 2026
Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVEAya Awwad, Upasana Das Adhikari, Tricia H Burdo, et al.
Biorxiv : the Preprint Server for Biology|December 4, 2023
SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedbackCamila H Coelho, Nathaniel Bloom, Sydney I Ramirez, et al.
Antimicrobial Agents and Chemotherapy|November 30, 2011
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 studyKimberly A Porter, Stephen R Cole, Joseph J Eron, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 4, 2016
Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy InitiationJyoti S Mathad, Nikhil Gupte, Ashwin Balagopal, et al.
Annals of Internal Medicine|October 7, 2024
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized TrialKathleen V Fitch, Markella V Zanni, Jennifer Manne-Goehler, et al.
Eclinicalmedicine|October 19, 2023
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialPrasanna Jagannathan, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|December 5, 2022
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19Carlee Moser, Jonathan Z Li, Joseph J Eron, et al.
JACC. Advances|July 10, 2026
Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE TrialSteven K Grinspoon, Christopher DeFilippi, Triin Umbleja, et al.
JCI Insight|November 15, 2022
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responsesSydney I Ramirez, Alba Grifoni, Daniela Weiskopf, et al.
Pageof 30

Showing results (211-220 of 298) with videos related to

Sort By:
Pageof 30
Pathogens & Immunity|May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 TrialKatya C Corado, Kara W Chew, Mark J Giganti, et al.
AIDS (London, England)|June 26, 2026
Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVEAya Awwad, Upasana Das Adhikari, Tricia H Burdo, et al.
Biorxiv : the Preprint Server for Biology|December 4, 2023
SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedbackCamila H Coelho, Nathaniel Bloom, Sydney I Ramirez, et al.
Antimicrobial Agents and Chemotherapy|November 30, 2011
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 studyKimberly A Porter, Stephen R Cole, Joseph J Eron, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 4, 2016
Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy InitiationJyoti S Mathad, Nikhil Gupte, Ashwin Balagopal, et al.
Annals of Internal Medicine|October 7, 2024
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized TrialKathleen V Fitch, Markella V Zanni, Jennifer Manne-Goehler, et al.
Eclinicalmedicine|October 19, 2023
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialPrasanna Jagannathan, Kara W Chew, Mark J Giganti, et al.
Open Forum Infectious Diseases|December 5, 2022
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19Carlee Moser, Jonathan Z Li, Joseph J Eron, et al.
JACC. Advances|July 10, 2026
Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE TrialSteven K Grinspoon, Christopher DeFilippi, Triin Umbleja, et al.
JCI Insight|November 15, 2022
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responsesSydney I Ramirez, Alba Grifoni, Daniela Weiskopf, et al.
Pageof 30